Morningstar28d
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) for potential securities law violations. Investors who have lost money in ...
The Globe and Mail21d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals(NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
The Globe and Mail25d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals(NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader ...
The Boston Globe28d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall Thursday. Vertex, based in ...
Yahoo Finance5d
Vertex, Inc. (VERX)
Jan. 09, 2025 (GLOBE NEWSWIRE ... Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and tax preparation software. S&P 500 components ...
Joplin Globe24d
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P. Morgan Healthcare ...
Joplin Globe27d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Nasdaq27d
Channel Therapeutics Corporation Comments on Vertex Pharmaceuticals' Phase 2 Data for NaV1.8 Inhibitor and Outlines NaV1.7 Therapeutic Approach
Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
manilatimes3d
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR ...
Morningstar7d
Royalty Pharma Announces Dividend Increase
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE ... Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche ...
manilatimes29d
Olympia Pharmaceuticals Announces the Launch of Sister Brand, Wesley Pharmaceuticals, in Honor of Beloved Employee
Dec. 18, 2024 (GLOBE ... Pharmaceuticals marks a significant milestone for Olympia, not only in terms of growth but also in tribute to the memory of Wesley Loomis, a cherished employee and family ...